Surgery Partners’ second quarter results were received positively by the market, with management highlighting that revenue and adjusted EBITDA came in ahead ...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the outpatient & specialty care stocks, including Surgery Partners (NASDAQ:SGRY) and it...
Healthcare company Surgery Partners (NASDAQ:SGRY) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 2.7% year on year to $848.9 million. Th...
Surgery Partners (NASDAQ:SGRY) reported second-quarter 2026 revenue and adjusted EBITDA above its internal expectations, while reaffirming its full-year outlook ahead of the anticipated sale of its Idaho Falls market operations to Intermountain Health.
The company reported net revenue of approximat
Healthcare company Surgery Partners (NASDAQ:SGRY) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.7% year on year to $...
Healthcare company Surgery Partners (NASDAQ:SGRY) will be announcing earnings results this Monday before market hours. Here’s what to expect. Surgery Partner...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
What Happened? Shares of healthcare company Surgery Partners (NASDAQ:SGRY) jumped 2.7% in the morning session after Cantor Fitzgerald reiterated its "Overwei...
Looking back on outpatient & specialty care stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Surgery Partners (NASDAQ:SGRY...
Surgery Partners currently trades at $15.10 per share and has shown little upside over the past six months, posting a small loss of 2.7%. The stock also fell...
Outpatient surgery giant or home-based respiratory care leader, which business model stands out as healthcare spending patterns evolve and margins diverge?
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Surgery Partners’ first quarter saw revenue growth above Wall Street expectations, with management attributing performance to stability across its surgical f...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged...
Healthcare company Surgery Partners (NASDAQ:SGRY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.5% year on year to $8...
Healthcare company Surgery Partners (NASDAQ:SGRY) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.5% year on year to $...
Healthcare company Surgery Partners (NASDAQ:SGRY) will be announcing earnings results this Tuesday before the bell. Here’s what to expect. Surgery Partners b...
